The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill

Because medical illness is associated with increased inflammation and an increased risk for treatment-resistant major depressive disorder, anti-cytokine therapy may represent a novel, and especially efficacious, treatment for depression. We hypothesized that blockade of the interleukin (IL)-6 signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Jennifer M., Costanzo, Erin S., Singh, Suraj, Yin, Ziyan, Szabo, Aniko, Pawar, Deepa S., Hillard, Cecilia J., Rizzo, J. Douglas, D’Souza, Anita, Pasquini, Marcelo, Coe, Christopher L., Irwin, Michael R., Raison, Charles L., Drobyski, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812704/
https://www.ncbi.nlm.nih.gov/pubmed/33462203
http://dx.doi.org/10.1038/s41398-020-01164-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812704/
https://www.ncbi.nlm.nih.gov/pubmed/33462203
http://dx.doi.org/10.1038/s41398-020-01164-y

Ejemplares similares